TL;DR
An oral GLP-1 that isn't a peptide. 11.2% weight loss at 72 weeks. No Rybelsus fasting.
What is it? A small-molecule oral GLP-1 receptor agonist (LY3502970) from Eli Lilly, licensed from Chugai in 2018. Not a peptide, so no absorption-enhancer tricks or morning fasts.
What does it do? Binds the GLP-1 receptor at a non-orthosteric pocket. Downstream effects match injectable GLP-1s: appetite suppression, glucose-dependent insulin release, glucagon inhibition, and slowed gastric emptying.
Does the evidence hold up? Phase 3 ATTAIN-1 (NEJM 2025) cut weight 11.2% at 36 mg vs 2.1% placebo over 72 weeks. Phase 3 ACHIEVE-1 (Rosenstock, NEJM, PMID 40544435) reduced HbA1c across doses in early type 2 diabetes. Regulatory submissions initiated late 2025.
Who uses it? In Eli Lilly's clinical trial network only. FDA review began late 2025. If approved, positioned for type 2 diabetes and obesity.
Bottom line? The first non-peptide GLP-1 through Phase 3. Approval is the next beat.
What It Is
Orforglipron (development code LY3502970) is an oral, non-peptide, small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) being developed by Eli Lilly for the treatment of type 2 diabetes and obesity/overweight. The molecule was originally discovered by Chugai Pharmaceutical in Japan and licensed to Eli Lilly in 2018. It is taxonomically distinct from every other GLP-1 receptor agonist currently approved or in advanced development: all approved GLP-1 RAs (exenatide, liraglutide, dulaglutide, semaglutide) are peptides, and oral semaglutide (Rybelsus) depends on the absorption-enhancer SNAC plus a 30-minute fasting window with ≤120 mL of water to achieve any meaningful bioavailability. Orforglipron is a true small molecule — it survives the gastrointestinal environment, absorbs through the intestinal wall through passive and carrier-mediated routes, and requires no food or water restriction at dosing (Ma et al., Diabetes Therapy).
Mechanistically, orforglipron activates GLP-1R from a non-peptide binding pocket structurally distinct from the orthosteric peptide-binding site. Kawai and colleagues (Nature 2020) published the cryo-EM structure of the GLP-1R–orforglipron complex, revealing the molecular basis for small-molecule activation — the compound binds a pocket spanning the extracellular side of transmembrane helices 1, 2, 3, and 7, inducing conformational changes that propagate to the intracellular Gαs-coupling site. The pharmacodynamic signature at downstream effectors (cAMP, insulin secretion, gastric emptying, appetite) is functionally similar to the peptide agonist class, though biased-agonism differences at the β-arrestin arm produce distinct receptor-desensitization kinetics.
Orforglipron has advanced rapidly through the clinical development pathway. Phase 1 single- and multiple-ascending-dose studies in healthy volunteers (Pratt 2023, Diabetes Obes Metab 25:2634-2641) established the PK / PD foundation. Phase 1b in T2D (Pratt 2023, PMID 37264711) confirmed HbA1c and body weight reductions. Phase 2 dose-finding in T2D (Frias et al., Lancet 2023; 402:472-483) and obesity (Wharton et al., N Engl J Med 2023;389:877-888; PMID 37342912) established efficacy across a broad dose range with safety consistent with the injectable GLP-1 class. The Phase 3 program — ACHIEVE for type 2 diabetes and ATTAIN for obesity — reported pivotal positive results in 2025.
As of April 2026, orforglipron is under regulatory review. Eli Lilly announced initiation of global regulatory submissions in late 2025 after the successful completion of the Phase 3 program. Launch, if approved, would reshape access to GLP-1-class therapy by eliminating the injection barrier and the food / water restrictions of oral semaglutide.
Mechanism of Action
- Non-peptide GLP-1R agonism — Orforglipron binds a small-molecule-accessible pocket of GLP-1R distinct from the peptide-binding orthosteric site. Activation produces Gαs-coupling, adenylate cyclase activation, and cAMP elevation — the canonical GLP-1R signaling cascade (Kawai 2020, Nature, structural biology).
- Glucose-dependent insulinotropic effect — GLP-1R on pancreatic β-cells couples orforglipron binding to glucose-dependent insulin secretion. The glucose-dependence is critical — GLP-1 RAs (including orforglipron) do not drive insulin secretion at low plasma glucose, minimizing hypoglycemia risk compared with sulfonylureas.
- Glucagon suppression — GLP-1R activation on pancreatic α-cells suppresses inappropriate glucagon secretion during hyperglycemia.
- Delayed gastric emptying — Central vagal and direct GI GLP-1R signaling slows gastric emptying, blunts postprandial glucose excursions, and extends satiety.
- Hypothalamic appetite suppression — Central GLP-1R in the arcuate nucleus, paraventricular nucleus, and NTS (nucleus tractus solitarius) mediates reduction in food intake — the primary mechanism behind weight loss.
- Reward / food palatability modulation — GLP-1R expression in mesolimbic reward circuits modulates food-reward valuation, reducing hedonic eating.
- Pharmacokinetics — once-daily oral — Tmax ~5–7 hours after oral administration. Half-life supports once-daily dosing. Unlike oral semaglutide, bioavailability is not meaningfully altered by coadministered food or water (Ma et al., Diabetes Ther).
- CYP metabolism — Primarily metabolized by CYP3A4. Clinically relevant interactions with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) and inducers (rifampin, phenytoin, carbamazepine, St John's wort) are expected.
- Species cross-reactivity note — Orforglipron is a full agonist at human GLP-1R but has limited cross-reactivity at rodent GLP-1R — human-specific pharmacology that required humanized GLP-1R mouse lines for preclinical efficacy characterization.
- Biased-agonism profile — Functionally comparable cAMP / insulin-secretion signaling to peptide GLP-1 RAs but modestly distinct β-arrestin recruitment, which may underlie differences in receptor-desensitization kinetics. Clinical significance of this difference is under investigation.
- No GIP receptor activity — Unlike tirzepatide (Lilly's GLP-1/GIP dual agonist), orforglipron is a pure GLP-1 single-target agonist. This may limit peak weight-loss magnitude relative to tirzepatide while simplifying the mechanism and adverse-event profile. Orforglipron's value proposition is oral administration plus GLP-1-class efficacy, not peak efficacy.
- No glucagon receptor activity — Orforglipron does not engage the glucagon receptor, distinguishing it from dual GLP-1/glucagon or triple GLP-1/GIP/glucagon agonists (retatrutide, mazdutide) in development.
- Intestinal absorption pathway — Orforglipron is absorbed through passive diffusion and carrier-mediated pathways in the small intestine. Its lipophilicity supports reasonable oral bioavailability without the need for absorption enhancers (in contrast to oral semaglutide which requires SNAC-mediated absorption enhancement).
What the Research Shows
- Phase 1 healthy volunteers (Pratt 2023) — Single- and multiple-ascending-dose study establishing PK, safety, and pharmacodynamic effects in healthy adults (Diabetes Obes Metab 25:2634-2641).
- Phase 1b T2D (Pratt 2023, PMID 37264711) — Multiple-ascending-dose in T2D patients; meaningful HbA1c and body-weight reductions with AE profile consistent with the GLP-1 class.
- Phase 2 T2D dose-finding (Frias 2023, Lancet 402:472-483) — 12-week dose-response in adults with T2D; dose-dependent HbA1c reductions, body-weight reductions, and GI-predominant AE profile.
- Phase 2 obesity (Wharton 2023, NEJM 389:877-888; PMID 37342912) — 36-week Phase 2 in adults with obesity. Weight reductions scaled with dose; highest-dose cohort achieved body-weight reductions approaching injectable semaglutide benchmarks.
- Phase 3 ACHIEVE-1 (Rosenstock 2025, NEJM 393:11; PMID 40544435; NCT05971940) — Phase 3, double-blind, placebo-controlled trial in 559 adults with early T2D treated by diet / exercise alone. 1:1:1:1 randomization to orforglipron 3, 12, 36 mg or placebo once daily for 40 weeks. Significant HbA1c reduction across all three doses vs placebo; BMI reductions scaled with dose.
- Phase 3 ATTAIN-1 obesity (Wharton 2025, NEJMoa2511774) — 72-week multinational phase 3 in adults with obesity / overweight. Weight reductions of −7.5% (6 mg), −8.4% (12 mg), −11.2% (36 mg) vs −2.1% placebo (all p<0.001). 54.6% of the 36-mg cohort achieved ≥10% weight reduction; 36.0% achieved ≥15%; 18.4% achieved ≥20%.
- Phase 3 ATTAIN-2 obesity + T2D (Aug 2025 topline) — Adults with obesity/overweight and comorbid T2D. 36-mg orforglipron once daily achieved 10.5% weight reduction (~22.9 lbs) vs 2.2% placebo; A1c reduction 1.8% vs placebo. 75% of highest-dose patients achieved A1c ≤6.5% (ADA non-diabetic threshold).
- Additional Phase 3 program — ACHIEVE-2/3/4 in T2D on background therapy (metformin, SGLT2i, insulin) and ATTAIN-3/Maintain programs for obesity extension / maintenance.
- Structural biology (Kawai 2020, Nature) — Cryo-EM structure of GLP-1R bound to orforglipron (LY3502970) defining the non-peptide binding pocket and mechanism of small-molecule receptor activation.
- Food-effect study (Ma 2023, Diabetes Ther) — No clinically meaningful food effect on orforglipron PK — distinct from oral semaglutide, which requires fasting administration.
- Cardiovascular signal — Consistent-with-class reductions in systolic blood pressure, triglycerides, and non-HDL cholesterol reported in ATTAIN-2; dedicated CV outcomes trial status evolving.
Research Strength
Orforglipron has one of the most thorough development pipelines of any current investigational GLP-1 RA: multiple Phase 3 trials across T2D (ACHIEVE), obesity (ATTAIN), and obesity plus comorbid T2D (ATTAIN-2), with consistent positive data across thousands of randomized patients. The Phase 3 evidence base at the point of regulatory submission is stronger than most peptide-class GLP-1 RAs at their equivalent development stage.
Human Data
- Phase 1 SAD/MAD healthy volunteers — Pratt 2023 (Diabetes Obes Metab 25:2634-2641). PK, safety, and pharmacodynamic foundation.
- Phase 1b T2D MAD (PMID 37264711) — Pratt 2023. Meaningful HbA1c and body-weight reductions.
- Phase 2 T2D (Frias 2023, Lancet 402:472-483) — Dose-response in T2D.
- Phase 2 obesity (Wharton 2023, NEJM; PMID 37342912) — 36-week obesity efficacy and safety.
- Phase 3 ACHIEVE-1 (Rosenstock 2025, NEJM; PMID 40544435; NCT05971940) — Early T2D, 40 weeks. Pivotal HbA1c data.
- Phase 3 ATTAIN-1 (Wharton 2025, NEJM; NEJMoa2511774) — Obesity, 72 weeks. Pivotal weight-loss data.
- Phase 3 ATTAIN-2 (2025 topline) — Obesity + T2D comorbidity.
- Phase 3 ACHIEVE-2, -3, -4 — T2D on background oral antidiabetic / insulin therapy.
- Additional ATTAIN / ACHIEVE / ORIGIN programs — Extending to maintenance, cardiovascular outcomes, adolescent obesity, and specific subpopulations.
- Pharmacokinetics across populations — PK characterization in Japanese, elderly, and renal / hepatic subpopulations to support global approval.
Dosing from the Literature
Investigational dosing across the Phase 3 program converged on three active doses administered once daily without food or water restriction. The following summarizes the Phase 3 regimens; approved labeling (if / when approval occurs) may narrow the range.
| Indication / Trial | Dose | Titration | Notes |
|---|
| ACHIEVE-1 Phase 3 (early T2D) | 3, 12, or 36 mg once daily | Titrated monthly from starting dose | 40-week double-blind placebo-controlled primary endpoint. |
| ATTAIN-1 Phase 3 (obesity) | 6, 12, or 36 mg once daily | Titrated monthly | 72-week weight-reduction endpoint. |
| ATTAIN-2 Phase 3 (obesity + T2D) | 36 mg once daily (top-dose cohort) | Titrated monthly | Both weight and A1c co-primary. |
| Administration | With or without food | No water restriction | Distinct from oral semaglutide Rybelsus which requires fasting administration with ≤120 mL water and 30-minute wait. |
| Concomitant medications | Standard of care | As indicated | Background metformin permitted in ACHIEVE-2/3/4; SGLT2i / insulin in advanced arms. |
Dosing Disclaimer
Orforglipron is investigational. No approved indication or prescribing label exists as of April 2026. Investigational doses described here are research-trial regimens. Once regulatory approval is issued, the label will govern clinical dosing.
Reconstitution & Storage
Orforglipron is an oral small-molecule tablet. No reconstitution is required — a distinguishing feature from every peptide GLP-1 RA currently approved.
| Form | Strength | Administration | Notes |
|---|
| Oral tablet (investigational) | 3, 6, 12, 36 mg (Phase 3 dose strengths) | Once daily with or without food | Swallow whole; no crushing or splitting studied. |
| Storage | Room temperature | Protect from moisture | No refrigeration required (unlike injectable GLP-1 RAs). |
- No injection supplies needed — Pens, needles, sharps disposal irrelevant.
- No food restriction — Distinct advantage over oral semaglutide.
- No water restriction — Swallow normally with whatever water the patient chooses.
- Once-daily dosing — Consistent timing recommended for optimal adherence.
- No cold-chain requirement — Oral small-molecule tablet; simpler logistics than peptide GLP-1 RAs.
→ Reconstitution not applicable — see calculator for injectable GLP-1 peers
Side Effects & Risks
Important
Orforglipron is not yet FDA-approved and remains investigational. GI adverse events match the GLP-1 class. Worth discussing with your doctor before joining a trial or waiting on approval.
- GI adverse events (class effect) — Nausea, vomiting, diarrhea, and constipation are the dominant AEs, consistent with the GLP-1 RA class. Dose- and titration-dependent; largely transient and peak during titration.
- Abdominal pain / discomfort — Frequently reported, typically mild to moderate; may persist longer than nausea in some patients.
- Decreased appetite / early satiety — Expected mechanism; contributes to intended weight reduction.
- Hypoglycemia — Generally uncommon as monotherapy because of glucose-dependent insulinotropic mechanism; risk increases when combined with sulfonylureas or insulin.
- Gallbladder adverse events — Cholelithiasis and cholecystitis reported in the GLP-1 class, including orforglipron Phase 3 data; risk related to rapid weight loss.
- Pancreatitis — Class warning; incidence low but requires vigilance with abdominal pain symptoms.
- Thyroid C-cell tumors (class boxed warning) — GLP-1 RAs carry a black-box warning for rodent thyroid C-cell tumor signal; human relevance uncertain but contraindication applies in personal or family history of medullary thyroid carcinoma or MEN-2.
- Diabetic retinopathy — Rapid glycemic improvement has been associated with transient retinopathy worsening in some GLP-1 RA trials; baseline retinopathy screening advised in T2D patients.
- Cardiovascular — Favorable effects on systolic blood pressure, triglycerides, non-HDL cholesterol observed in ATTAIN-2; dedicated CV outcomes data evolving.
- CYP3A4 drug interactions — Strong inhibitors (ketoconazole, clarithromycin) may increase orforglipron exposure; strong inducers (rifampin, phenytoin, carbamazepine, St John's wort) may reduce it. Dose adjustment or alternative therapy may be needed.
- Pregnancy and lactation — GLP-1 RA class is generally not recommended during pregnancy due to limited human data and animal reproductive findings.
- Discontinuation effects — Weight regain commonly observed after GLP-1 RA discontinuation, consistent with the class; sustained benefit requires sustained therapy.
- Renal / hepatic impairment — Pharmacokinetic characterization ongoing; no clinically meaningful dose adjustment reported to date.
Bloodwork & Monitoring
- HbA1c — Baseline and every 3 months in T2D users.
- Fasting glucose — Monitor especially when combining with insulin or sulfonylureas (hypoglycemia risk).
- Comprehensive metabolic panel (CMP) — Baseline renal and hepatic function; annual or more frequent as clinically indicated.
- Lipid panel — Baseline; class produces favorable triglyceride and non-HDL cholesterol reductions.
- Body weight / body composition — Monitor at each visit; DEXA if detailed composition data needed.
- Blood pressure — Class reduces systolic BP modestly; antihypertensive doses may need downward adjustment.
- Pancreas-related symptoms — Amylase / lipase if suspected pancreatitis (abdominal pain, persistent nausea).
- Gallbladder symptoms — Ultrasound if RUQ pain; cholelithiasis rate elevated in GLP-1 class.
- Thyroid function / palpation — Not routinely indicated; new thyroid nodules warrant evaluation.
- Diabetic retinopathy screening — Baseline fundoscopy in T2D users before initiation of any GLP-1 RA.
Commonly Stacked With
Orforglipron is not a research peptide and has no community-use stacking culture. Clinical combination considerations focus on standard-of-care background therapy in diabetes and obesity.
Metformin
First-line oral therapy in T2D. ACHIEVE-2 evaluated orforglipron on background metformin. Pharmacodynamically complementary with no meaningful PK interaction.
SGLT2 inhibitors (empagliflozin, dapagliflozin)
Cardiovascular- and renal-protective oral T2D therapy. Complementary mechanism; layered use in advanced T2D.
Insulin (in advanced T2D)
Complementary where insulin is clinically required; glucose-dependent insulinotropic effect of orforglipron reduces total insulin requirement. Monitor for hypoglycemia when combined.
Do not combine. Both are GLP-1 RA class (tirzepatide is GLP-1 / GIP dual). Use of orforglipron plus an injectable GLP-1 or dual agonist is pharmacodynamically duplicative and increases AE burden without additional benefit.
Standard lifestyle intervention
Every Phase 3 orforglipron trial paired the drug with structured lifestyle intervention (diet, physical activity counseling). Effect sizes above reflect combined drug + lifestyle; results without lifestyle backbone are smaller.
→ Check compound compatibility in the Stack Builder
What to Expect — Timeline (Phase 3 data)
Based on Phase 3 ATTAIN and ACHIEVE data, expected timelines for weight-loss and glycemic response in trial-equivalent populations:
- Weeks 1–4 (titration start) — Starting low dose (3 mg). Early GI tolerability phase. Nausea and reduced appetite typically emerge in the first week. Weight change early in the course is modest.
- Weeks 4–12 — Titration continues monthly. Appetite reduction and early satiety consolidate. Initial weight loss trajectory establishes — typically 2–5% reduction from baseline at 12 weeks depending on dose cohort.
- Weeks 12–24 — Weight loss continues steadily. HbA1c reductions in T2D users become clinically meaningful. GI AEs diminish for most users who tolerated titration.
- Weeks 24–40 (ACHIEVE-1 endpoint) — Near-maximal HbA1c reduction in T2D. Dose-dependent: 3, 12, 36 mg all produced statistically significant HbA1c reductions vs placebo at 40 weeks.
- Weeks 40–72 (ATTAIN-1 endpoint) — Continued weight loss accumulation. Final weight-reduction means (vs −2.1% placebo): −7.5% at 6 mg, −8.4% at 12 mg, −11.2% at 36 mg. 54.6% of the 36-mg cohort achieved ≥10% reduction; 36.0% achieved ≥15%; 18.4% achieved ≥20%.
- After discontinuation — Consistent with the injectable GLP-1 class, weight regain is common after discontinuation. Sustained therapy supports sustained weight reduction; this is a chronic-disease management framework, not a time-limited "course" approach.
- Individual variability — Responder analysis in ATTAIN-1 showed substantial tail distribution — a subset of patients achieved very large reductions (>20%), while others achieved smaller responses. Genetic and metabolic factors driving inter-individual variability are under investigation.
- Non-responders — As with injectable GLP-1 RAs, a minority of users do not achieve clinically meaningful weight reduction. Dose escalation within the 3–36 mg range may recover response in some; beyond-label escalation has not been studied.
Quick Compare — Orforglipron vs Oral Semaglutide vs Injectable GLP-1 Class
Orforglipron will, if approved, enter a crowded GLP-1-class market. Comparing it to the closest clinical alternatives:
| Feature | Orforglipron (LY3502970) | Oral Semaglutide (Rybelsus) | Injectable Semaglutide (Ozempic / Wegovy) | Tirzepatide (Mounjaro / Zepbound) |
|---|
| Molecular class | Small molecule (non-peptide) | Peptide | Peptide | Peptide (GLP-1 + GIP dual) |
| Route | Oral tablet | Oral tablet | Weekly SC injection | Weekly SC injection |
| Food / water restriction | None | Fasting required; ≤120 mL water; 30 min wait | None (injection) | None (injection) |
| Frequency | Once daily | Once daily | Once weekly | Once weekly |
| Weight loss (highest-dose obesity) | −11.2% at 72 weeks (ATTAIN-1, 36 mg) | Modest; oral formulation primarily glycemic | −14.9% at 68 weeks (STEP-1, 2.4 mg) | −20.9% at 72 weeks (SURMOUNT-1, 15 mg) |
| HbA1c reduction (T2D) | Dose-dependent (ACHIEVE-1) | ~1.0–1.4% (PIONEER) | ~1.5–1.8% (SUSTAIN) | ~1.9–2.4% (SURPASS) |
| Approved indications | Under review (pending 2026) | T2D | T2D (Ozempic); obesity (Wegovy) | T2D (Mounjaro); obesity (Zepbound) |
| CV outcomes data | Under development | SOUL trial | SELECT (positive) | SURPASS-CVOT (ongoing) |
| Storage | Room temperature | Room temperature | Refrigerated, room temp in use | Refrigerated, room temp in use |
| Key advantage | Oral + no restrictions + near-injectable efficacy | Oral option (restrictions) | Proven CV benefit + established safety | Largest weight-loss magnitude |
Practical interpretation: If approved, orforglipron's market position would be as the most patient-friendly oral GLP-1 RA — offering weight-loss and glycemic efficacy approaching the injectable class without the injection burden or the strict fasting / water restrictions that limit oral semaglutide adoption. Tirzepatide will remain the highest-magnitude weight-loss drug in the class; orforglipron's value proposition is accessibility and adherence rather than peak efficacy.
Regulatory Status
Current Status — April 2026
Orforglipron is not yet approved by any regulatory agency. Eli Lilly announced the initiation of global regulatory submissions in late 2025 following the successful ATTAIN-2 readout. FDA, EMA, PMDA (Japan), MHRA (U.K.), and other national regulator filings are progressing. Target decisions are expected across 2026.
If approved, the expected label indications are type 2 diabetes and obesity / weight management in adults, with dose strengths and titration recommendations defined by the regulator. Approved labeling will govern clinical use; doses and populations studied in the Phase 3 program will inform the label.
Orforglipron is not specifically named on the WADA Prohibited List as of April 2026. Once approved, GLP-1 RA class is not prohibited in sport, though individual federations may adopt case-specific restrictions. Athletes should consult their sport-specific federation.
Orforglipron is not on the FDA Category 2 Bulk Drug Substances list (as a small molecule, it would not fall under the peptide-compounding framework) and is not part of HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. It will move through the standard NDA pathway as a small-molecule drug.
Cost & Access
Orforglipron is not yet commercially available. It is accessible only through clinical trial participation (ATTAIN and ACHIEVE programs through Eli Lilly) or expanded access where applicable.
If and when approved, orforglipron will be distributed through Eli Lilly as a prescription branded small-molecule tablet. The launch would join semaglutide (Novo Nordisk, Rybelsus oral; Ozempic and Wegovy injectables) and tirzepatide (Lilly, Mounjaro and Zepbound) in the GLP-1 / incretin class.
Because orforglipron is a small molecule rather than a peptide, it is not within the scope of the HHS / FDA peptide compounding framework. Compounded orforglipron will not be a legitimate commercial pathway; any such "compounded orforglipron" sold through compounding pharmacies or gray-market channels is outside the approved regulatory framework. Patients seeking GLP-1 therapy should access approved products through licensed pharmacies.
Availability information as of April 2026. Actual approval, pricing, and prescription status will be determined by regulatory authorities and the sponsor. Kalios does not sell compounds.
Related Compounds
People researching Orforglipron often also look at these:
Daily GLP-1 receptor agonist (Victoza / Saxenda). First-generation GLP-1 with shorter half-life.
Triple GLP-1 / GIP / glucagon agonist. The most potent obesity drug in Phase III, ~24% body weight reduction.
Weekly GLP-1 receptor agonist (Trulicity). Approved for type 2 diabetes and cardiovascular risk reduction.
Viking Therapeutics' dual GLP-1 / GIP agonist in Phase II/III for obesity.
Key References
- Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1001-1013. PMID: 40544435. DOI: 10.1056/NEJMoa2505669. NCT05971940.
- Wharton S, Aronne LJ, Stefanski A, Pratt E, Liu R, Hayes PS, Ahmad NN, Li B, Fernández Landó L, Nunes M, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2511774 (ATTAIN-1, 72-week Phase 3 obesity).
- Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888. PMID: 37342912.
- Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D, Pyrah I, Hartman ML, Bumol TF. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472-483. PMID: 37369232.
- Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, Haupt A, Benson C. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9):2642-2649. PMID: 37264711.
- Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, Sloop KW, Benson C. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634-2641. PMID: 37264690.
- Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA, Kobilka TS, Coghlan MP, Willard FS, Kawabe Y, Kobilka BK, Sloop KW. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959-29967. PMID: 33177239.
- Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024;15(4):819-832. PMID: 38349475.
- Chow E, Yang A, Chung CHL, Chan JCN. A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer. Pharmaceuticals (Basel). 2022;15(4):442. PMID: 35455439. (Companion metformin pharmacology context for T2D combinations.)
- Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial (ATTAIN-2), triggering global regulatory submissions this year for the treatment of obesity. Press release, Aug 26 2025.
- ClinicalTrials.gov. ACHIEVE-1 (NCT05971940); ATTAIN-1 (NCT05869903); ATTAIN-2 and related Phase 3 protocols under the orforglipron program.
- Luna Ceron E, Reddy SD, Kattamuri L, et al. Current insights, advantages and challenges of small-molecule glucagon-like peptide 1 receptor agonists: a scoping review. J Brown Hosp Med. 2025;4:19-32.
Last updated: April 2026 | Profile authored by Kalios Peptides research team